Nikhil C. Munshi
尼基尔·蒙希
MD
Director, Basic and Correlative Sciences, Jerome Lipper Multiple Myeloma Center多发性骨髓瘤中心基础与转化科学主任
👥Biography 个人简介
Dr. Nikhil Munshi is a global leader in multiple myeloma research at Dana-Farber. He pioneered CAR-T cell therapy trials for myeloma, including ide-cel (bb2121) and cilta-cel, transforming treatment for relapsed/refractory disease. His work spans genomics, immunotherapy, and novel therapeutic combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CAR-T Therapy for Myeloma
Led pivotal KarMMa and CARTITUDE clinical trials establishing ide-cel and cilta-cel as transformative therapies for relapsed/refractory multiple myeloma, achieving deep and durable responses.
Myeloma Genomics
Conducted landmark genomic studies characterizing clonal evolution and mutational landscape in multiple myeloma, informing precision medicine strategies.
Representative Works 代表性著作
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine (2021)
KarMMa trial demonstrating unprecedented response rates with BCMA-targeted CAR-T therapy in heavily pretreated myeloma patients.
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine (2022)
CARTITUDE-1 results showing deep remissions with cilta-cel, including high rates of MRD negativity.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 尼基尔·蒙希 的研究动态
Follow Nikhil C. Munshi's research updates
留下邮箱，当我们发布与 Nikhil C. Munshi（Dana-Farber Cancer Institute, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment